SynAct Financial Statements From 2010 to 2026
| SYNACT Stock | 22.75 0.55 2.48% |
Check SynAct Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SynAct Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . SynAct financial statements analysis is a perfect complement when working with SynAct Pharma Valuation or Volatility modules.
SynAct |
SynAct Pharma AB Company Return On Equity Analysis
SynAct Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current SynAct Pharma Return On Equity | -1.49 |
Most of SynAct Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SynAct Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, SynAct Pharma AB has a Return On Equity of -1.4916. This is much lower than that of the sector and significantly lower than that of the Return On Equity industry. The return on equity for all Sweden stocks is notably higher than that of the company.
SynAct Pharma AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SynAct Pharma's current stock value. Our valuation model uses many indicators to compare SynAct Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SynAct Pharma competition to find correlations between indicators driving SynAct Pharma's intrinsic value. More Info.SynAct Pharma AB is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value SynAct Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for SynAct Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About SynAct Pharma Financial Statements
SynAct Pharma stakeholders use historical fundamental indicators, such as SynAct Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although SynAct Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in SynAct Pharma's assets and liabilities are reflected in the revenues and expenses on SynAct Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in SynAct Pharma AB. Please read more on our technical analysis and fundamental analysis pages.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in SynAct Stock
SynAct Pharma financial ratios help investors to determine whether SynAct Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SynAct with respect to the benefits of owning SynAct Pharma security.